文献速递心胸血管麻醉

羟钴胺(维生素B12a)用于心肺转流后血管升压药难治性低血压:病例系列

Use of Hydroxocobalamin (Vitamin B12a) in Patients With Vasopressor Refractory Hypotension After Cardiopulmonary Bypass: A Case Series.
PubMed 文献 · Anesth Analg · 2019-01-01

该病例系列回顾了24例心肺转流(CPB)后接受羟钴胺(维生素B12a)作为疑似血管麻痹综合征(VS)挽救治疗的患者,机构已制定其使用指南。给药后血流动力学参数与血管升压药需求出现有利变化,但指南VS标准并非一致满足;结果支持继续研究B12a在CPB相关VS中的作用。

要点

  • CPB后疑似VS患者使用B12a后血流动力学与升压药需求呈有利变化
  • 指南VS标准在实际用药人群中并非一致满足
  • B12a因成本与稀缺性宜按机构指南作为挽救治疗

核心结论

  • CPB后接受B12a的患者血流动力学参数与血管升压药需求出现有利变化,支持继续研究B12a用于CPB相关VS。

研究设计与样本

  • 单中心病例系列,纳入24例CPB后接受B12a的患者,回顾其血流动力学变量与血管升压药需求。

主要发现

  • B12a给药后血流动力学参数与血管升压药需求出现有利变化。
  • 指南中VS标准在用药患者中并非一致满足。

临床怎么用

  • 在CPB后疑似VS且对血管升压药反应不佳时,可参照机构指南将B12a作为挽救治疗使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hydroxocobalamin (vitamin B12a) is an emerging treatment for vasoplegic syndrome (VS) associated with cardiopulmonary bypass (CPB). Given its cost and scarcity, an institutional guideline for its use as a rescue treatment in cases of suspected VS was developed. Hemodynamic variables and vasopressor requirements were reviewed for a series of 24 post-CPB patients who received B12a. Favorable changes in hemodynamic parameters and vasopressor requirements were seen after B12a administration although guideline criteria for VS were inconsistently met. These findings support the continued study of B12a in patients with CPB-associated VS.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Armour S, Armour TK, Joppa WR, et al. Use of Hydroxocobalamin (Vitamin B12a) in Patients With Vasopressor Refractory Hypotension After Cardiopulmonary Bypass: A Case Series. Anesth Analg. 2019. PMID: 29979199. doi:10.1213/ANE.0000000000003648

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。